Your browser doesn't support javascript.
loading
Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients.
Fraser, Douglas D; Patel, Maitray A; Van Nynatten, Logan R; Martin, Claudio; Seney, Shannon L; Miller, Michael R; Daley, Mark; Slessarev, Marat; Cepinskas, Gediminas; Juneja, Ganeem K; Sabourin, Vanessa; Fox-Robichaud, Alison; Yeh, Calvin H; Kim, Paul Y; Badrnya, Sigrun; Oehler, Susanne; Miholits, Markus; Webb, Brian.
Afiliación
  • Fraser DD; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Patel MA; Pediatrics, Western University, London, ON, N6A 3K7, Canada.
  • Van Nynatten LR; Clinical Neurological Sciences, Western University, London, ON, N6A 3K7, Canada.
  • Martin C; Physiology & Pharmacology, Western University, London, ON, N6A 3K7, Canada.
  • Seney SL; Epidemiology, Western University, London, ON, N6A 3K7, Canada.
  • Miller MR; Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Daley M; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Slessarev M; Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Cepinskas G; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Juneja GK; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Sabourin V; Pediatrics, Western University, London, ON, N6A 3K7, Canada.
  • Fox-Robichaud A; Epidemiology, Western University, London, ON, N6A 3K7, Canada.
  • Yeh CH; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Kim PY; Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Badrnya S; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Oehler S; Medical Biophysics, Western University, London, ON, N6A 3K7, Canada.
  • Miholits M; Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
  • Webb B; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.
Heliyon ; 9(1): e12704, 2023 Jan.
Article en En | MEDLINE | ID: mdl-36594041
ABSTRACT
Critically ill patients infected with SARS-CoV-2 display adaptive immunity, but it is unknown if they develop cross-reactivity to variants of concern (VOCs). We profiled cross-immunity against SARS-CoV-2 VOCs in naturally infected, non-vaccinated, critically ill COVID-19 patients. Wave-1 patients (wild-type infection) were similar in demographics to Wave-3 patients (wild-type/alpha infection), but Wave-3 patients had higher illness severity. Wave-1 patients developed increasing neutralizing antibodies to all variants, as did patients during Wave-3. Wave-3 patients, when compared to Wave-1, developed more robust antibody responses, particularly for wild-type, alpha, beta and delta variants. Within Wave-3, neutralizing antibodies were significantly less to beta and gamma VOCs, as compared to wild-type, alpha and delta. Patients previously diagnosed with cancer or chronic obstructive pulmonary disease had significantly fewer neutralizing antibodies. Naturally infected ICU patients developed adaptive responses to all VOCs, with greater responses in those patients more likely to be infected with the alpha variant, versus wild-type.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Heliyon Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Heliyon Año: 2023 Tipo del documento: Article País de afiliación: Canadá